Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: Evidence to date

Felix A. Mensah, Jean Pierre Blaize, Locke J. Bryan

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

The importance of the phosphatidylinositol-3-kinase (PI3K) pathway in cell survival and proliferation has made it an attractive target in cancer therapy. The development of small molecule inhibitors for the PI3K pathway continues to provide treatment alternatives across a range of malignancy types. Several agents, including idelalisib, copanlisib and duvelisib, not only inhibit the PI3K pathway, but also have effects on associated mechanisms including the ATK and mTOR pathways. The advent of PI3K-specific small molecular inhibitors has led to increased efficacy with avoidance of an excessive toxicity profile. Key enzymes of the PI3K pathway exhibit differing expression in tissue types and roles in tumor pathogenesis. Copanlisib (BAY 80-6946) is a pan-specific PI3K small molecule inhibitor for four key isoforms with increased activity against PI3Kα and PI3Kδ, both important in B-cell malignancies. Follicular lymphoma is one of the most common indolent B-cell non-Hodgkin lymphomas worldwide. Follicular lymphoma like other indolent B-cell non-Hodgkin lymphomas is beleaguered by high relapse rates and the need for subsequent therapy options. Based on efficacy and a limited toxicity profile, copanlisib received accelerated US Food and Drug Administration approval for the treatment of adult patients with relapsed follicular lymphoma following two lines of therapy. Here, we review the development of copanlisib and the role of this agent in the treatment of follicular lymphoma.

Original languageEnglish (US)
Pages (from-to)4817-4827
Number of pages11
JournalOncoTargets and Therapy
Volume11
DOIs
StatePublished - Jan 1 2018

Fingerprint

Phosphatidylinositol 3-Kinase
Follicular Lymphoma
B-Cell Lymphoma
Therapeutics
Non-Hodgkin's Lymphoma
Neoplasms
Drug Approval
2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo(1,2-c)quinazolin-4-yl)pyrimidine-5-carboxamide
Cell Survival
Protein Isoforms
B-Lymphocytes
Cell Proliferation
Recurrence
Food

Keywords

  • Copanlisib
  • Follicular lymphoma
  • Kinase inhibitor
  • Non-hodgkin lymphoma
  • PI3K

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma : Evidence to date. / Mensah, Felix A.; Blaize, Jean Pierre; Bryan, Locke J.

In: OncoTargets and Therapy, Vol. 11, 01.01.2018, p. 4817-4827.

Research output: Contribution to journalReview article

@article{0ae512b00e36479dbd6566f40a9d754e,
title = "Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: Evidence to date",
abstract = "The importance of the phosphatidylinositol-3-kinase (PI3K) pathway in cell survival and proliferation has made it an attractive target in cancer therapy. The development of small molecule inhibitors for the PI3K pathway continues to provide treatment alternatives across a range of malignancy types. Several agents, including idelalisib, copanlisib and duvelisib, not only inhibit the PI3K pathway, but also have effects on associated mechanisms including the ATK and mTOR pathways. The advent of PI3K-specific small molecular inhibitors has led to increased efficacy with avoidance of an excessive toxicity profile. Key enzymes of the PI3K pathway exhibit differing expression in tissue types and roles in tumor pathogenesis. Copanlisib (BAY 80-6946) is a pan-specific PI3K small molecule inhibitor for four key isoforms with increased activity against PI3Kα and PI3Kδ, both important in B-cell malignancies. Follicular lymphoma is one of the most common indolent B-cell non-Hodgkin lymphomas worldwide. Follicular lymphoma like other indolent B-cell non-Hodgkin lymphomas is beleaguered by high relapse rates and the need for subsequent therapy options. Based on efficacy and a limited toxicity profile, copanlisib received accelerated US Food and Drug Administration approval for the treatment of adult patients with relapsed follicular lymphoma following two lines of therapy. Here, we review the development of copanlisib and the role of this agent in the treatment of follicular lymphoma.",
keywords = "Copanlisib, Follicular lymphoma, Kinase inhibitor, Non-hodgkin lymphoma, PI3K",
author = "Mensah, {Felix A.} and Blaize, {Jean Pierre} and Bryan, {Locke J.}",
year = "2018",
month = "1",
day = "1",
doi = "10.2147/OTT.S142264",
language = "English (US)",
volume = "11",
pages = "4817--4827",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma

T2 - Evidence to date

AU - Mensah, Felix A.

AU - Blaize, Jean Pierre

AU - Bryan, Locke J.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The importance of the phosphatidylinositol-3-kinase (PI3K) pathway in cell survival and proliferation has made it an attractive target in cancer therapy. The development of small molecule inhibitors for the PI3K pathway continues to provide treatment alternatives across a range of malignancy types. Several agents, including idelalisib, copanlisib and duvelisib, not only inhibit the PI3K pathway, but also have effects on associated mechanisms including the ATK and mTOR pathways. The advent of PI3K-specific small molecular inhibitors has led to increased efficacy with avoidance of an excessive toxicity profile. Key enzymes of the PI3K pathway exhibit differing expression in tissue types and roles in tumor pathogenesis. Copanlisib (BAY 80-6946) is a pan-specific PI3K small molecule inhibitor for four key isoforms with increased activity against PI3Kα and PI3Kδ, both important in B-cell malignancies. Follicular lymphoma is one of the most common indolent B-cell non-Hodgkin lymphomas worldwide. Follicular lymphoma like other indolent B-cell non-Hodgkin lymphomas is beleaguered by high relapse rates and the need for subsequent therapy options. Based on efficacy and a limited toxicity profile, copanlisib received accelerated US Food and Drug Administration approval for the treatment of adult patients with relapsed follicular lymphoma following two lines of therapy. Here, we review the development of copanlisib and the role of this agent in the treatment of follicular lymphoma.

AB - The importance of the phosphatidylinositol-3-kinase (PI3K) pathway in cell survival and proliferation has made it an attractive target in cancer therapy. The development of small molecule inhibitors for the PI3K pathway continues to provide treatment alternatives across a range of malignancy types. Several agents, including idelalisib, copanlisib and duvelisib, not only inhibit the PI3K pathway, but also have effects on associated mechanisms including the ATK and mTOR pathways. The advent of PI3K-specific small molecular inhibitors has led to increased efficacy with avoidance of an excessive toxicity profile. Key enzymes of the PI3K pathway exhibit differing expression in tissue types and roles in tumor pathogenesis. Copanlisib (BAY 80-6946) is a pan-specific PI3K small molecule inhibitor for four key isoforms with increased activity against PI3Kα and PI3Kδ, both important in B-cell malignancies. Follicular lymphoma is one of the most common indolent B-cell non-Hodgkin lymphomas worldwide. Follicular lymphoma like other indolent B-cell non-Hodgkin lymphomas is beleaguered by high relapse rates and the need for subsequent therapy options. Based on efficacy and a limited toxicity profile, copanlisib received accelerated US Food and Drug Administration approval for the treatment of adult patients with relapsed follicular lymphoma following two lines of therapy. Here, we review the development of copanlisib and the role of this agent in the treatment of follicular lymphoma.

KW - Copanlisib

KW - Follicular lymphoma

KW - Kinase inhibitor

KW - Non-hodgkin lymphoma

KW - PI3K

UR - http://www.scopus.com/inward/record.url?scp=85058715703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058715703&partnerID=8YFLogxK

U2 - 10.2147/OTT.S142264

DO - 10.2147/OTT.S142264

M3 - Review article

AN - SCOPUS:85058715703

VL - 11

SP - 4817

EP - 4827

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -